Firestone Karen, an insider at Amylyx Pharmaceuticals Inc (AMLX), acquired 63,100 shares of the company on December 22, 2025, at a price of $12.45 per share, totaling approximately $786,000. Following this transaction, Karen holds a total of 63,100 shares in the company.
This purchase comes as Amylyx Pharmaceuticals, a biotechnology firm based in Cambridge, Massachusetts, focuses on therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The company went public on January 7, 2022, and currently has a market capitalization of $1.3 billion, with an earnings per share (EPS) of -2.50.
The upcoming earnings report is scheduled for May 6, 2026, with an estimated EPS of -0.30 and no expected revenue. Insider buying often reflects an executive’s confidence in the company’s future, as they typically have access to non-public information. However, such transactions should be viewed in the context of broader market trends and not as sole indicators for investment decisions. Investors are encouraged to analyze patterns of insider activity over time and across multiple insiders for a more comprehensive understanding.
Insider transactions are reported to the SEC, providing transparency regarding how company executives view their stock. While Karen's purchase is a noteworthy data point, it is essential to consider it alongside other fundamental and technical factors when evaluating the company's prospects.